UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

Blood, 2010-09, Vol.116 (12), p.2122-2126

2010

Link zum Volltext

Verfügbarkeit prüfen

P1448: CHARACTERISATION OF QUALITY OF LIFE‐LINKED PATIENT‐REPORTED OUTCOMES THROUGH A DIGITAL AND CONTINUOUS REMOTE MONITORING ECOSYSTEM IN SICKLE CELL DISEASE

HemaSphere, 2023-08, Vol.7 (S3), p.e53344bb-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

P1441: REAL‐WORLD OUTCOMES AND DIGITALLY MONITORED QUALITY OF LIFE IN CRIZANLIZUMAB‐TREATED PATIENTS WITH SICKLE CELL DISEASE

HemaSphere, 2023-08, Vol.7 (S3), p.e25264f3-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

High EVI1 Expression Predicts Outcome in Younger Adult Patients With Acute Myeloid Leukemia and Is Associated With Distinct Cytogenetic Abnormalities

Journal of clinical oncology, 2010-04, Vol.28 (12), p.2101-2107

2010

Link zum Volltext

Verfügbarkeit prüfen

Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1

Blood, 2011-01, Vol.117 (1), p.234-241

2011

Link zum Volltext

Verfügbarkeit prüfen

EVI1 is critical for the pathogenesis of a subset of MLL-AF9–rearranged AMLs

Blood, 2012-06, Vol.119 (24), p.5838-5849

2012

Link zum Volltext

Verfügbarkeit prüfen

An update review of new therapies in sickle cell disease: the prospects for drug combinations

Expert opinion on pharmacotherapy, 2024-02, Vol.25 (2), p.157-170

2024

Link zum Volltext

Verfügbarkeit prüfen

DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia

Cancer cell, 2010-01, Vol.17 (1), p.13-27

2010

Link zum Volltext

Verfügbarkeit prüfen

The acute pain crisis in sickle cell disease: What can be done to improve outcomes?

Blood reviews, 2024-05, Vol.65, p.101194-101194, Article 101194

2024

Link zum Volltext

Verfügbarkeit prüfen

Expanded eligibility for emerging therapies in sickle cell disease in the UK – crizanlizumab and voxelotor

British journal of haematology, 2022-05, Vol.197 (4), p.502-504

2022

Link zum Volltext

Verfügbarkeit prüfen

Treatment with IMR-687, a Highly Selective PDE9 Inhibitor, Increases HbF and Reduces VOCs in Adults with Sickle Cell Disease in a Long-Term, Phase 2a, Open-Label Extension Study

Blood, 2021-11, Vol.138 (Supplement 1), p.2046-2046

2021

Link zum Volltext

Verfügbarkeit prüfen

Protecting vulnerable patients with inherited anaemias from unnecessary death during the COVID‐19 pandemic

British journal of haematology, 2020-05, Vol.189 (4), p.635-639

2020

Link zum Volltext

Verfügbarkeit prüfen

Improvement in Lymphoma CAR-T Outcomes over Time in the UK - CAR-T Learning Curve or Better Bridging?

Blood, 2022-11, Vol.140 (Supplement 1), p.4649-4651

2022

Link zum Volltext

Verfügbarkeit prüfen

Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients

Blood, 2020-11, Vol.136 (Supplement 1), p.29-30

2020

Link zum Volltext

Verfügbarkeit prüfen

Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients

Haematologica (Roma), 2020-11, Vol.105 (11), p.2651-2654

2020

Link zum Volltext

Verfügbarkeit prüfen

Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling

Haematologica (Roma), 2009-01, Vol.94 (1), p.131-134

2009

Link zum Volltext

Verfügbarkeit prüfen

Detection of CAR‐T19 cells in peripheral blood and cerebrospinal fluid: An assay applicable to routine diagnostic laboratories

Cytometry. Part B, Clinical cytometry, 2021-11, Vol.100 (6), p.622-631

2021

Link zum Volltext

Verfügbarkeit prüfen

Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia

Cancer cell, 2005-04, Vol.7 (4), p.375-386

2005

Link zum Volltext

Verfügbarkeit prüfen

Pharmacogenomics of acute leukemia

Annual review of pharmacology and toxicology, 2006-01, Vol.46 (1), p.317-353

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)
Japanisch
(4)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

P1448: CHARACTERISATION OF QUALITY OF LIFE‐LINKED PATIENT‐REPORTED OUTCOMES THROUGH A DIGITAL AND CONTINUOUS REMOTE MONITORING ECOSYSTEM IN SICKLE CELL DISEASE

P1441: REAL‐WORLD OUTCOMES AND DIGITALLY MONITORED QUALITY OF LIFE IN CRIZANLIZUMAB‐TREATED PATIENTS WITH SICKLE CELL DISEASE

High EVI1 Expression Predicts Outcome in Younger Adult Patients With Acute Myeloid Leukemia and Is Associated With Distinct Cytogenetic Abnormalities

Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1

EVI1 is critical for the pathogenesis of a subset of MLL-AF9–rearranged AMLs

An update review of new therapies in sickle cell disease: the prospects for drug combinations

DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia

The acute pain crisis in sickle cell disease: What can be done to improve outcomes?

Expanded eligibility for emerging therapies in sickle cell disease in the UK – crizanlizumab and voxelotor

Treatment with IMR-687, a Highly Selective PDE9 Inhibitor, Increases HbF and Reduces VOCs in Adults with Sickle Cell Disease in a Long-Term, Phase 2a, Open-Label Extension Study

A national service for delivering CD19 CAR‐Tin large B‐cell lymphoma – The UK real‐world experience

Protecting vulnerable patients with inherited anaemias from unnecessary death during the COVID‐19 pandemic

Improvement in Lymphoma CAR-T Outcomes over Time in the UK - CAR-T Learning Curve or Better Bridging?

Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients

Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients

Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling

Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia

A national service for delivering CD19 CAR‐T in large B‐cell lymphoma – The UK real‐world experience

Detection of CAR‐T19 cells in peripheral blood and cerebrospinal fluid: An assay applicable to routine diagnostic laboratories

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes

Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia

An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model

Pharmacogenomics of acute leukemia

Suchergebnisse filtern